Form 4 for DXCM Dexcom
Accepted 2022-09-12 00:00:00 ET · period of report 2022-09-08 · accession 0001093557-22-000157 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-12 | 2022-09-08 | DXCM | Selvaraj Shelly Ramasamy | SVP CIO | A - Grant | $0.00 | +4,051 | 49.9K | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-08 | A | A | 4,051 | $0.00 | 49,942 | D | — | — | (F1) This RSU Award was granted pursuant to the Amended and Restated 2015 Equity Incentive Plan, in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. (F2) Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 31,107 unvested restricted stock units, 4,051 of which were granted on September 8, 2022 and shall all vest on September 8, 2023, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,308 of which were granted on March 8, 2020 and shall vest through March 8, 2023. |